Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: Results of a phase 1 study among healthy subjects

Kelly E. Dooley, Patrick Sayre, Julie Borland, Elizabeth Purdy, Shuguang Chen, Ivy Song, Amanda Peppercorn, Stephanie Everts, Stephen Piscitelli, Charles Flexner

Research output: Contribution to journal › Article › peer-review

127 Scopus citations

Fingerprint

Dive into the research topics of 'Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: Results of a phase 1 study among healthy subjects'. Together they form a unique fingerprint.

Medicine & Life Sciences